IASLC - EGFR Mutant NSCLC Post Osimertinib
In this episode of Lung Cancer Considered, host Dr. Stephen Liu leads a new Virtual Tumor Board on EGFR mutant NSCLC and acquired resistance. Dr. Liu is joined by two thoracic medical oncologists who are both global experts in targeted therapy.